Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases

Autor: Dan Lipsker, Olivier Dereure, Nicolas Terrail, B. Bergeret, M. Dandurand, Valerie Reymann, Didier Bessis, Aurélie Du-Thanh

Publikováno v: Journal of the European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology, Wiley, 2021, 35 (2), pp.e113-e115. ⟨10.1111/jdv.16839⟩

Lenalidomide (LND), a synthetic thalidomide analog mainly used in haematological malignancies has proved efficient and well-tolerated in small case series of refractory Cutaneous Lupus Erythematosus (CLE). A retrospective survey of CLE patients treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::511ddd75454a65c0aaabb183759967f6
https://pubmed.ncbi.nlm.nih.gov/32730681